HS Pipeline Watch: MoonLake Immunotherapeutics’ Sonelokimab Advances to Phase 3
The first patients have been screened at a U.S. trial site in MoonLake Immunotherapeutics’ global Phase 3 clinical program, VELA, evaluating sonelokimab in hidradenitis suppurativa (HS). Sonelokimab is a Nanobody designed to directly target sites of inflammation by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers and to penetrate difficult-to-reach inflamed tissues. The initiation of this […]